[Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
Zgliczyński
Stefan
S
Borówka
Andrzej
A
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D010018:Osteomalacia / Q000139:chemically induced* / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal